新型冠状病毒感染与银屑病之间关系的研究进展

doi:10.35541/cjd.20220869

Abstract

Abstract: 【Abstract】 During the coronavirus disease 2019 （COVID-19） pandemic, widespread attention has been paid to the management of psoriasis, and more and more researchers have explored the relationships between psoriasis and COVID-19 from different perspectives. This review summarizes the impact of the use of biological agents on COVID-19 in patients with psoriasis, and the interaction between psoriasis and COVID-19, aiming to provide more reliable guidance on diagnosis and treatment of psoriasis for dermatologists and patients, and to provide a reference for future research.

Key words: Psoriasis, Coronavirus infections, Biological agents, Hydroxychloroquine, COVID-19

Chen Jiaqi, Zhang Jin, Tang Jun. Relationships between coronavirus disease 2019 and psoriasis[J]. Chinese Journal of Dermatology, 2025, 58(1): 84-88.doi:10.35541/cjd.20220869

References ［55］

［1］	Lebwohl M, Rivera⁃Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID⁃19?［J］. J Am Acad Dermatol, 2020,82（5）:1217⁃1218. doi: 10.1016/j.jaad.2020.03. 031.
［2］	Gisondi P, Piaserico S, Naldi L, et al. Incidence rates of hospitalization and death from COVID⁃19 in patients with psoriasis receiving biological treatment: a Northern Italy experience［J］. J Allergy Clin Immunol, 2021,147（2）:558⁃560.e1. doi: 10.1016/j.jaci.2020.10.032.
［3］	Piaserico S, Gisondi P, Cazzaniga S, et al. Lack of evidence for an increased risk of severe COVID⁃19 in psoriasis patients on biologics: a cohort study from Northeast Italy［J］. Am J Clin Dermatol, 2020,21（5）:749⁃751. doi: 10.1007/s40257⁃020⁃00552⁃w.
［4］	Baniandrés⁃Rodríguez O, Vilar⁃Alejo J, Rivera R, et al. Incidence of severe COVID⁃19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis［J］. J Am Acad Dermatol, 2021,84（2）:513⁃517. doi: 10.1016/j.jaad.2020.10.046.
［5］	Talamonti M, Galluzzo M, Chiricozzi A, et al. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID⁃19 pandemic: risk analysis from the PSO⁃BIO⁃COVID observational study［J］. Expert Opin Biol Ther, 2021,21（2）:271⁃277. doi: 10.1080/14712598.2021.1853698.
［6］	Conti A, Lasagni C, Bigi L, et al. Evolution of COVID⁃19 infection in four psoriatic patients treated with biological drugs［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:e360⁃e361. doi: 10.1111/jdv.16587.
［7］	Damiani G, Pacifico A, Bragazzi NL, et al. Biologics increase the risk of SARS⁃CoV⁃2 infection and hospitalization, but not ICU admission and death: real⁃life data from a large cohort during red⁃zone declaration［J］. Dermatol Ther, 2020,33（5）:e13475. doi: 10.1111/dth.13475.
［8］	Valenti M, Facheris P, Pavia G, et al. Non⁃complicated evolution of COVID⁃19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab［J］. Dermatol Ther, 2020,33（4）:e13708. doi: 10.1111/dth.13708.
［9］	Ohmura SI, Homma Y, Hanai S, et al. Successful use of certolizumab pegol for refractory psoriatic arthritis triggered by COVID⁃19 infection［J］. Intern Med, 2022,61（3）:433⁃438. doi: 10.2169/internalmedicine.8643⁃21.
［10］	Carugno A, Gambini DM, Raponi F, et al. Coronavirus disease 2019 （COVID⁃19） rash in a psoriatic patient treated with secukinumab: is there a role for interleukin 17?［J］. Dermatol Ther, 2020,33（6）:e14011. doi: 10.1111/dth.14011.
［11］	Messina F, Piaserico S. SARS⁃CoV⁃2 infection in a psoriatic patient treated with IL⁃23 inhibitor［J］. J Eur Acad Dermatol Venereol, 2020,34（6）:e254⁃e255. doi: 10.1111/jdv.16468.
［12］	Kiss N, Lőrincz K, Medvecz M, et al. Coronavirus disease 2019 in a psoriatic patient with concomitant chronic obstructive pulmonary disease under treatment with risankizumab［J］. Dermatol Ther, 2020,33（6）:e14186. doi: 10.1111/dth.14186.
［13］	Zumla A, Hui DS, Azhar EI, et al. Reducing mortality from 2019⁃nCoV: host⁃directed therapies should be an option［J］. Lancet, 2020,395（10224）:e35⁃e36. doi: 10.1016/S0140⁃6736（20）30305⁃ 6.
［14］	Mroz M, Mućka S, Miodońska M, et al. Influence of SARS⁃CoV⁃2 virus infection on the course of psoriasis during treatment with biological drugs［J］. Medicina （Kaunas）, 2021,57（9）:881. doi: 10.3390/medicina57090881.
［15］	Meng Y, Zeng F, Sun H, et al. Clinical characteristics and outcomes of patients with COVID⁃19 and psoriasis［J］. J Med Virol, 2022,94（12）:5850⁃5857. doi: 10.1002/jmv.28085.
［16］	Zhang M, Bai X, Cao W, et al. The influence of corticosteroids, immunosuppressants and biologics on patients with inflammatory bowel diseases, psoriasis and rheumatic diseases in the era of COVID⁃19: a review of current evidence［J］. Front Immunol, 2021,12:677957. doi: 10.3389/fimmu.2021.677957.
［17］	Penso L, Dray⁃Spira R, Weill A, et al. Psoriasis⁃related treatment exposure and hospitalization or in⁃hospital mortality due to COVID⁃19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France［J］. Br J Dermatol, 2022,186（1）:59⁃68. doi: 10.1111/bjd.20659.
［18］	Gisondi P, Zaza G, Del Giglio M, et al. Risk of hospitalization and death from COVID⁃19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment［J］. J Am Acad Dermatol, 2020,83（1）:285⁃287. doi: 10.1016/j.jaad.2020.04.085.
［19］	Kridin K, Schonmann Y, Tzur Bitan D, et al. Coronavirus disease 2019 （COVID⁃19）⁃associated hospitalization and mortality in patients with psoriasis: a population⁃based study［J］. Am J Clin Dermatol, 2021,22（5）:709⁃718. doi: 10.1007/s40257⁃021⁃00605⁃8.
［20］	Kara Polat A, Oguz Topal I, Karadag AS, et al. The impact of COVID⁃19 in patients with psoriasis: a multicenter study in Istanbul［J］. Dermatol Ther, 2021,34（1）:e14691. doi: 10.1111/dth.14691.
［21］	Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS⁃CoV⁃2 in Wuhan, China［J］. Allergy, 2020,75（7）:1730⁃1741. doi: 10.1111/all.14238.
［22］	Pablos JL, Galindo M, Carmona L, et al. Clinical outcomes of hospitalised patients with COVID⁃19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study［J］. Ann Rheum Dis, 2020,79（12）:1544⁃1549. doi: 10.1136/annrheumdis⁃2020⁃218296.
［23］	Kutlu Ö, Metin A. Dermatological diseases presented before COVID⁃19: are patients with psoriasis and superficial fungal infections more vulnerable to the COVID⁃19?［J］. Dermatol Ther, 2020,33（4）:e13509. doi: 10.1111/dth.13509.
［24］	Yiu Z, Harding⁃Oredugba G, Griffiths C, et al. Risk of COVID⁃19 infection in adult patients with atopic eczema and psoriasis: a single⁃centre cross⁃sectional study［J］. Br J Dermatol, 2021,185（2）:441⁃443. doi: 10.1111/bjd.20062.
［25］	Haberman R, Axelrad J, Chen A, et al. Covid⁃19 in immune⁃mediated inflammatory diseases ⁃ case series from New York［J］. N Engl J Med, 2020,383（1）:85⁃88. doi: 10.1056/NEJMc 2009567.
［26］	Criado PR, Ianhez M, Silva de Castro CC, et al. COVID⁃19 and skin diseases: results from a survey of 843 patients with atopic dermatitis, psoriasis, vitiligo and chronic urticaria［J］. J Eur Acad Dermatol Venereol, 2022,36（1）:e1⁃e3. doi: 10.1111/jdv. 17635.
［27］	Eder L, Croxford R, Drucker AM, et al. COVID⁃19 hospitalizations, intensive care unit stays, ventilation, and death among patients with immune⁃mediated inflammatory diseases compared to controls［J］. J Rheumatol, 2022,49（5）:523⁃530. doi: 10.3899/jrheum.211012.
［28］	Gianfrancesco M, Hyrich KL, Al⁃Adely S, et al. Characteristics associated with hospitalisation for COVID⁃19 in people with rheumatic disease: data from the COVID⁃19 Global Rheumatology Alliance physician⁃reported registry［J］. Ann Rheum Dis, 2020,79（7）:859⁃866. doi: 10.1136/annrheumdis⁃2020⁃217871.
［29］	Carugno A, Gambini DM, Raponi F, et al. COVID⁃19 and biologics for psoriasis: a high⁃epidemic area experience⁃Bergamo, Lombardy, Italy［J］. J Am Acad Dermatol, 2020,83（1）:292⁃294. doi: 10.1016/j.jaad.2020.04.165.
［30］	Magnano M, Balestri R, Bardazzi F, et al. Psoriasis, COVID⁃19, and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment［J］. Dermatol Ther, 2020,33（4）:e13706. doi: 10.1111/dth.13706.
［31］	Gisondi P, Facheris P, Dapavo P, et al. The impact of the COVID⁃19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience［J］. Br J Dermatol, 2020,183（2）:373⁃374. doi: 10.1111/bjd.19158.
［32］	Rademaker M, Agnew K, Anagnostou N, et al. Psoriasis and infection. A clinical practice narrative［J］. Australas J Dermatol, 2019,60（2）:91⁃98. doi: 10.1111/ajd.12895.
［33］	Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry （PSOLAR）［J］. JAMA Dermatol, 2015,151（9）:961⁃969. doi: 10.1001/jamadermatol.2015.0718.
［34］	Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID⁃19 outcomes in patients with psoriasis⁃insights from a global registry⁃based study［J］. J Allergy Clin Immunol, 2021,147（1）:60⁃71. doi: 10.1016/j.jaci.2020.10.007.
［35］	Kampylafka E, Simon D, d′Oliveira I, et al. Disease interception with interleukin⁃17 inhibition in high⁃risk psoriasis patients with subclinical joint inflammation⁃data from the prospective IVEPSA study［J］. Arthritis Res Ther, 2019,21（1）:178. doi: 10.1186/s13075⁃019⁃1957⁃0.
［36］	Cronin JG, Mesher D, Purdie K, et al. Beta⁃papillomaviruses and psoriasis: an intra⁃patient comparison of human papillomavirus carriage in skin and hair［J］. Br J Dermatol, 2008,159（1）:113⁃119. doi: 10.1111/j.1365⁃2133.2008.08627.x.
［37］	Agarwal A, Tripathy T, Kar BR. Guttate flare in a patient with chronic plaque psoriasis following COVID⁃19 infection: a case report［J］. J Cosmet Dermatol, 2021,20（10）:3064⁃3065. doi: 10. 1111/jocd.14396.
［38］	Pala E, Melikoğlu M, Erkayman MH. Pediatric COVID⁃19 patient with exacerbated generalized pustular psoriasis［J］. Rev Soc Bras Med Trop, 2021,54:e0318. doi: 10.1590/0037⁃8682⁃0318⁃2021.
［39］	Bozonnat A, Assan F, LeGoff J, et al. SARS⁃CoV⁃2 infection inducing severe flare up of deficiency of interleukin thirty⁃six （IL⁃36） receptor antagonist （DITRA） resulting from a mutation invalidating the activating cleavage site of the IL⁃36 receptor antagonist［J］. J Clin Immunol, 2021,41（7）:1511⁃1514. doi: 10. 1007/s10875⁃021⁃01076⁃6.
［40］	Miladi R, Janbakhsh A, Babazadeh A, et al. Pustular psoriasis flare⁃up in a patient with COVID⁃19［J］. J Cosmet Dermatol, 2021,20（11）:3364⁃3368. doi: 10.1111/jocd.14508.
［41］	Shakoei S, Ghanadan A, Hamzelou S. Pustular psoriasis exacerbated by COVID⁃19 in a patient with the history of psoriasis［J］. Dermatol Ther, 2020,33（6）:e14462. doi: 10.1111/dth.14462.
［42］	Shahidi Dadras M, Diab R, Ahadi M, et al. Generalized pustular psoriasis following COVID⁃19［J］. Dermatol Ther, 2021,34（1）:e14595. doi: 10.1111/dth.14595.
［43］	Demiri J, Abdo M, Tsianakas A. Erythrodermic psoriasis after COVID⁃19［J］. Hautarzt, 2022,73（2）:156⁃159. doi: 10.1007/s00105⁃021⁃04931⁃0.
［44］	Nasiri S, Araghi F, Tabary M, et al. A challenging case of psoriasis flare⁃up after COVID⁃19 infection［J］. J Dermatolog Treat, 2020,31（5）:448⁃449. doi: 10.1080/09546634.2020.1764904.
［45］	Ozaras R, Berk A, Ucar DH, et al. Covid⁃19 and exacerbation of psoriasis［J］. Dermatol Ther, 2020,33（4）:e13632. doi: 10.1111/dth.13632.
［46］	Novelli L, Motta F, Ceribelli A, et al. A case of psoriatic arthritis triggered by SARS⁃CoV⁃2 infection［J］. Rheumatology （Oxford）, 2021,60（1）:e21⁃e23. doi: 10.1093/rheumatology/keaa691.
［47］	Zhou Q, Vadakekolathu J, Watad A, et al. SARS⁃CoV⁃2 infection induces psoriatic arthritis flares and enthesis resident plasmacytoid dendritic cell type⁃1 interferon inhibition by JAK antagonism offer novel spondyloarthritis pathogenesis insights［J］. Front Immunol, 2021,12:635018. doi: 10.3389/fimmu.2021. 635018.
［48］	Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID⁃19⁃related death using OpenSAFELY［J］. Nature, 2020,584（7821）:430⁃436. doi: 10.1038/s41586⁃020⁃2521⁃4.
［49］	Kamiya K, Kishimoto M, Sugai J, et al. Risk factors for the development of psoriasis［J］. Int J Mol Sci, 2019,20（18）:4347. doi: 10.3390/ijms20184347.
［50］	Shindo E, Shikano K, Kawazoe M, et al. A case of generalized pustular psoriasis caused by hydroxychloroquine in a patient with systemic lupus erythematosus［J］. Lupus, 2019,28（8）:1017⁃1020. doi: 10.1177/0961203319854139.
［51］	Gravani A, Gaitanis G, Zioga A, et al. Synthetic antimalarial drugs and the triggering of psoriasis ⁃ do we need disease⁃specific guidelines for the management of patients with psoriasis at risk of malaria?［J］. Int J Dermatol, 2014,53（3）:327⁃330. doi: 10.1111/ijd.12231.
［52］	Ullah A, Zeb H, Khakwani Z, et al. Hydroxychloroquine⁃induced inverse psoriasis［J］. BMJ Case Rep, 2019,12（2）:e224619. doi: 10.1136/bcr⁃2018⁃224619.
［53］	Kutlu Ö, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID⁃19: will cases of psoriasis increase after COVID⁃19 pandemic?［J］. Dermatol Ther, 2020,33（4）:e13383. doi: 10.1111/dth.13383.
［54］	Wolf R, Schiavo AL, Lombardi ML, et al. The in vitro effect of hydroxychloroquine on skin morphology in psoriasis［J］. Int J Dermatol, 1999,38（2）:154⁃157. doi: 10.1046/j.1365⁃4362.1999. 00574.x.
［55］	Said A, Bock S, Lajqi T, et al. Chloroquine promotes IL⁃17 production by CD4+ T cells via p38⁃dependent IL⁃23 release by monocyte⁃derived Langerhans⁃like cells［J］. J Immunol, 2014,193（12）:6135⁃6143. doi: 10.4049/jimmunol.1303276.

[1]	Xu Zhuohong, Hu Yu, Gu Heng. Role of mesenchymal stem cell?derived exosomes in skin diseases [J]. Chinese Journal of Dermatology, 2025, 58(3): 20220881-e20220881.
[2]	Jin Lan, Qiu Yun, Wang Weijia, Kang Xiaojing, Ding Yuan. Clinical efficacy and safety of biological agents in the treatment of moderate-to-severe psoriasis in 124 elderly patients: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 47-52.
[3]	Wang Bo, Zheng Jie. Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs [J]. Chinese Journal of Dermatology, 2025, 58(1): 72-75.
[4]	Qiao Jiaxi, Xia Ping, Chen Liuqing. Analysis of dermoscopic and reflectance confocal microscopic features of psoriatic lesions before and after treatment with secukinumab [J]. Chinese Journal of Dermatology, 2024, 57(9): 825-829.
[5]	Dou Jinfa, Wang Jianbo, Zhang Shuai, Li Jianguo, Liu Hongwei, Zhang Shoumin. Analysis of changes in disease status and their influencing factors in patients with moderate to severe plaque psoriasis receiving biologic therapy during the coronavirus disease 2019 pandemic: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2024, 57(8): 739-742.
[6]	Lin Ziyuan, Pang Tianyi, Wu Jingwen, Jin Hui, . Role of polycyclic aromatic hydrocarbons in the occurrence and development of inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(8): 765-769.
[7]	Sui Changlin, Chang Xiao, Zhao Qi, Zhu Wei. Psoriasis induced by anti-tumor targeted therapy and immunotherapy [J]. Chinese Journal of Dermatology, 2024, 57(6): 570-574.
[8]	Hu Mengyao, Li Min, Chen Sihan, Wei Xuecui, Chen Yujie, Xu Song, Chen Xu, . Different regulatory effects of S100A8/A9 expressed by keratinocytes in three common inflammatory skin injury modes [J]. Chinese Journal of Dermatology, 2024, 57(5): 435-444.
[9]	China Dermatologist Association, Combination of Traditional and Western Medicine Dermatology. Diagnosis and treatment of erythrodermic psoriasis: a Chinese expert consensus statement （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 409-417.
[10]	Zhang Yuanwen, Sun Congqian, Pan Wendong. Off-label clinical application of botulinum toxin in dermatology [J]. Chinese Journal of Dermatology, 2024, 57(5): 471-475.
[11]	Guo Lan, Jin Hongzhong. Small-molecule/biological agents in the treatment of pruritus [J]. Chinese Journal of Dermatology, 2024, 57(5): 475-478.
[12]	Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2024, 57(5): 479-482.
[13]	Ding Rui, Zhang Weiliang, Li Jing, Chen Yujia, Li Junying. Dupilumab for the treatment of five cases of refractory endogenous hyperkeratotic hand-foot eczema [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230429-e20230429.
[14]	Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358.
[15]	Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus [J]. Chinese Journal of Dermatology, 2024, 57(4): 374-378.

Relationships between coronavirus disease 2019 and psoriasis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［55］

Related Articles 15

Metrics

Comments

Recommended 10